[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"progressive-pulmonary-fibrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:progressive-pulmonary-fibrosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,45,70,94,107,154,176,197,220,245],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053910","phase-3-study-of-the-efficacy-and-safety-of-inhaled-treprostinil-in-subjects-with-progressive-pulmonary-fibrosis-teton-ppf-100053910",false,"NCT05943535","Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)","A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)","Inclusion Criteria:\n\n1. Subject gives voluntary informed consent to participate in the study.\n2. Subject is ≥18 years of age, inclusive, at the time of signing informed consent.\n3. Subject has radiological evidence of pulmonary fibrosis of \\>10% extent on an HRCT scan in the previous 12 months (confirmed by central review).\n4. Subject has a diagnosis of PPF (other than IPF) that fulfills at least 1 of the following criteria for progression within 24 months of screening despite standard treatment of ILD, as assessed by the Investigator:\n\n   1. Clinically significant decline in % predicted FVC based on ≥10% relative decline\n   2. Marginal decline in % predicted FVC based on ≥5% to \\\u003C10% relative decline combined with worsening of respiratory symptoms\n   3. Marginal decline in % predicted FVC based on ≥5% to \\\u003C10% relative decline combined with increasing extent of fibrotic changes on chest imaging\n   4. Worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging\n5. FVC ≥45% predicted at Screening (confirmed by central review).\n6. Subjects must be on 1 of the following:\n\n   1. On nintedanib or pirfenidone for ≥90 days prior to Baseline and in the Investigator's opinion, are planning to continue treatment through the study\n   2. Not on treatment with nintedanib or pirfenidone for ≥90 days prior to Baseline and in the Investigator's opinion, not planning to initiate either treatment during the study.\n\n   Concomitant use of both nintedanib and pirfenidone is not permitted.\n7. Subjects treated with immunosuppressive agents (eg, mycophenolate, methotrexate, azathioprine, oral corticosteroids, rituximab) need to be on treatment for at least 120 days prior to Baseline and, in the Investigator's clinical opinion, must be refractory to treatment.\n8. Women of childbearing potential must be non-pregnant (as confirmed by a urine pregnancy test at Screening and Baseline) and non-lactating, and will agree to do 1 of the following:\n\n   1. Abstain from intercourse (when it is in line with their preferred and usual lifestyle)\n   2. Use 2 medically acceptable, highly effective forms of contraception for the duration of the study, and at least 30 days after discontinuing study drug.\n\n   i. Medically acceptable, highly effective forms of contraception can include approved hormonal contraceptives (oral, injectable, and implantable) and barrier methods (such as a condom or diaphragm) when used with a spermicide.\n\n   Women who are successfully sterilized (including hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal (defined as amenorrhea for at least 12 consecutive months) are not considered to be of reproductive potential.\n9. Males with a partner of childbearing potential must agree to use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.\n10. In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.\n\nExclusion Criteria:\n\n1. Subject is pregnant or lactating.\n2. Subject has primary obstructive airway physiology (forced expiratory volume in 1 second\u002FFVC \\\u003C0.70 at Screening) or greater extent of emphysema than fibrosis on HRCT (confirmed by central review).\n3. Subject has a diagnosis of IPF.\n4. Subject has shown intolerance or significant lack of efficacy to a prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to effectively titrate that therapy.\n5. Subject has received any PAH-approved therapy, including prostacyclin therapy (epoprostenol, treprostinil, iloprost, or beraprost; except for acute vasoreactivity testing), IP receptor agonists (selexipag), endothelin receptor antagonists, phosphodiesterase type 5 inhibitors (PDE5-Is), soluble guanylate cyclase stimulators, or activin signaling inhibitors (sotatercept) within 60 days prior to Baseline. As needed use of a PDE5-I for erectile dysfunction is permitted, provided no doses are taken within 48 hours prior to any study-related efficacy assessments.\n6. Subject is receiving \\>10 L\u002Fmin of oxygen supplementation by any mode of delivery at rest at Baseline.\n7. Exacerbation of ILD or active pulmonary or upper respiratory infection within 30 days prior to Baseline. Subjects must have completed any antibiotic or steroid regimens for treatment of the infection or acute exacerbation more than 30 days prior to Baseline to be eligible. If hospitalized for an acute exacerbation of ILD or a pulmonary or upper respiratory infection, subjects must have been discharged more than 90 days prior to Baseline to be eligible.\n8. Subject has uncontrolled cardiac disease, defined as myocardial infarction within 6 months prior to Baseline or unstable angina within 30 days prior to Baseline.\n9. Use of any other investigational drug\u002Fdevice or participation in any investigational study in which the subject received a medical intervention (ie, procedure, device, medication\u002Fsupplement) within 30 days prior to Screening. Subjects participating in non-interventional, observational, or registry studies are eligible.\n10. Acute pulmonary embolism within 90 days prior to Baseline.\n11. In the opinion of the Investigator, the subject has any condition that would interfere with the interpretation of study assessments or would impair study participation or cooperation.\n12. In the opinion of the Investigator, life expectancy \\\u003C12 months due to ILD or a concomitant illness.\n13. Subject has received nerandomilast within 60 days prior to Baseline.","ALL","18 Years",{"count":19,"type":20},698,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.",[26,27],"Progressive Pulmonary Fibrosis","Interstitial Lung Disease",[29,30,31],"Treprostinil","PPF","ILD","RECRUITING","2026-07-09",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2023-10-30",{"date":40,"type":20},"2027-11",{"name":42,"class":43},"United Therapeutics","INDUSTRY",165,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100589192","phase-2-an-extension-study-of-subjects-who-received-an-avalyn-inhaled-antifibrotic-agent-sail-100589192","NCT06951217","An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)","A Multinational, Long-Term, Safety and Tolerability, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [SAIL])","SAIL","Inclusion Criteria:\n\n* Previously participated in an Avalyn-sponsored inhaled antifibrotic clinical study for subjects with either idiopathic pulmonary fibrosis (IPF) (IPF subjects are excluded from the US and Canada) or progressive pulmonary fibrosis (PPF) and with the approval of the Study Physician.\n\nPrevious participation is defined as: Having completed the final visit of the Treatment Period on the full dose of study drug (either active or placebo).\n\n* Male subjects and female subjects of childbearing potential (FOCBP) agree to use highly effective contraception measures from the time of first dose of study drug (for the male subject) or the signing of the informed consent form (ICF) (for the female subject), during the study, and until 90 days after the last dose of study drug. Subjects agree not to donate eggs or sperm during the same period.\n\nExclusion Criteria:\n\n* Have not previously participated in an Avalyn-sponsored inhaled antifibrotic lead-in study or if the subject was permanently discontinued from the lead-in study for any reason. Subjects who discontinued study drug but continued to attend study visits are ineligible.\n* Subjects who experienced an exacerbation of asthma or of chronic obstructive pulmonary disease (COPD) requiring oral or systemic corticosteroids within 3 months of Day 1 (Screening\u002FBaseline Visit).\n* Subjects who experienced an acute exacerbation of IPF (IPF subjects are excluded from the US and Canada) or of PPF within 3 months of Day 1 (Screening\u002FBaseline Visit).\n* Participation in a concurrent clinical study or in a clinical study in which any other investigational drug product aside from the Avalyn nebulized antifibrotic medication from their lead-in study was administered within the previous 30 days, or 5 half-lives of the previously administered investigational product, whichever is shorter. Subjects may be enrolled in registries.\n* History of hypersensitivity and\u002For allergic reaction to pirfenidone or the excipients to be used in this study.",{"count":54,"type":20},340,[56],"PHASE2","This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE-008 study visit on the same day.",[26,59],"Idiopathic Pulmonary Fibrosis (IPF)","2026-07-01",{"date":62,"type":36},"2026-07-02",{"date":64,"type":36},"2025-04-17",{"date":66,"type":20},"2031-12-31",{"name":68,"class":43},"Avalyn Pharma Inc.",54,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100534422","phase-3-a-follow-up-study-to-test-long-term-treatment-with-nerandomilast-in-people-with-pulmonary-fibrosis-who-took-part-in-a-previous-study-with-nerandomilast-100534422","NCT06238622","A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast","An Open-label Extension Trial of the Long-term Safety and Efficacy of BI 1015550 Taken Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) (FIBRONEER™-ON)","FIBRONEER™-ON","Inclusion Criteria:\n\n1. Patients who completed treatment in the parent trials (1305-0014, 1305-0023, or 1305-0035) without prematurely discontinuing treatment permanently according to protocol (i.e. completed treatment with or without temporary treatment interruption)\n2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial\n3. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. WOCBP taking oral contraceptives (OCs) also have to ensure the use of one barrier method during sexual intercourse with their partner, e.g., condom to account for the risk of potentially reduced efficacy of the OCs in the event of severe vomiting and diarrhoea. For France, fertile males must be ready and able to use acceptable methods of birth control\n\nExclusion Criteria:\n\n1. Any disease that may put the patient at risk when participating in this trial at investigator's discretion.\n2. Patient exhibits suicidality, in the clinical judgment of the investigator or according to the following criteria at Visit 1:\n\n   * any suicidal behaviour (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behaviour)\n   * any suicidal ideation of type 4 or 5 in the Columbia-Suicide Severity Rating Scale (C-SSRS) (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent)\n3. Patients with clinically relevant severe depression at investigator's discretion or a Hospital Anxiety and Depression Scale (HADS) subscore \\>14 at Visit 1.\n4. An occurrence of malignant neoplasm other than appropriately treated basal cell carcinoma or in situ squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix at Visit 1.\n5. Patient will undergo lung transplantation, with an assigned date of surgery.\n6. Patients with a Body Mass index (BMI) \\\u003C18.5 kg\u002Fm² that experienced an additional, unexplained and clinically significant (\\>10%) weight loss during the parent trial\n7. At Visit 1, patients with ongoing Adverse Event of Special Interest (AESI), except for latent tuberculosis (suspected vasculitis, Drug Induced Liver Injury (DILI), severe infections) that led to temporary treatment interruption in the parent trial\n8. Patients who must or wish to take restricted medications or any drug considered likely to interfere with the safe conduct of the trial.\n\nFurther exclusion criteria apply.",{"count":79,"type":20},1700,[23],"This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550.\n\nThe goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need to go to the hospital, or die.\n\nEvery participant takes nerandomilast as tablets for up to 1 year and 10 months. The participants may also continue their regular treatment for pulmonary fibrosis during the study.\n\nParticipants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. Participants also regularly do lung function tests.",[83,26],"Idiopathic Pulmonary Fibrosis","2026-06-23",{"date":86,"type":36},"2026-06-24",{"date":88,"type":36},"2024-05-06",{"date":90,"type":20},"2027-05-05",{"name":92,"class":43},"Boehringer Ingelheim",372,{"id":95,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":24,"conditions":98,"keywords":99,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":105,"locationsCount":106},"100511753",{"count":19,"type":20},[23],[26,27],[29,30,31],"2026-06-17",{"date":102,"type":36},"2026-06-18",{"date":38,"type":36},{"date":40,"type":20},{"name":42,"class":43},160,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":153},"100630325","optimizing-the-follow-up-journey-in-interstitial-lung-disease-the-optimize-ild-2-trial-100630325","NCT07486206","Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial","OPTIMIZE-ILD-2: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Coordinated Follow-Up Circuit on Time Burden in Patients With Interstitial Lung Disease","OPTIMIZE-ILD-2","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Established diagnosis of interstitial lung disease (ILD).\n* Currently receiving antifibrotic therapy, immunosuppressive therapy, or both, as part of routine ILD care.\n* Under active follow-up at the participating ILD center.\n* Able to attend the required follow-up procedures included in the study visit.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Inability to complete the coordinated follow-up visit for non-medical reasons (e.g., logistical impossibility).\n* Clinical instability or acute illness interfering with planned follow-up procedures (such as respiratory infection, suspected ILD exacerbation, acute heart failure, or other acute conditions).\n* Participation in another interventional clinical trial that may alter visit frequency or follow-up structure.\n* Cognitive impairment preventing informed consent or completion of questionnaires.\n* Patient refusal to participate or refusal to allow data collection.",{"count":116,"type":20},152,[118],"NA","The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD). In routine clinical practice, follow-up workflows for ILD are frequently fragmented, requiring multiple hospital visits for pulmonary function tests, laboratory analysis, treatment administration, and consultations with various specialists, which increases the burden for both patients and caregivers. This study compares the standard follow-up care against an optimized circuit where all routine monitoring procedures and interdisciplinary consultations are pre-bundled and scheduled within a single, coordinated hospital visit.\n\nAll eligible patients under active ILD follow-up are included consecutively to ensure a pragmatic, real-world representation of the treated ILD population. The primary objective is to measure the total follow-up time burden, defined as the total home-to-home time required to complete the follow-up circuit. As a cross-sectional assessment within a longitudinal context, secondary objectives include assessing socioeconomic cost-burden, the environmental carbon footprint of the follow-up journey, health-related quality of life, and clinical frailty. Caregiver-related outcomes, including burden and experience measures, are contingent upon the presence of a primary caregiver and the provision of their independent informed consent.\n\nThe design of this protocol was informed by a patient focus group and is officially endorsed by the 'AIRE' Associació Catalana de Malalts i Trasplantats Pulmonars, ensuring a patient-centered approach that prioritizes follow-up efficiency and human impact.",[121,122,59,26,123],"Interstitial Lung Disease (ILD)","Fibrotic Interstitial Lung Disease","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",[27,31,125,83,26,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142],"Pulmonary Fibrosis","CTD-ILD","Fibrotic ILD","Antifibrotic Therapy","Immunosuppressive Therapy","Follow-Up Pathway","Follow-Up Care Coordination","Time Burden","Home-to-Home Time Burden","One-Day ILD Clinic","Health Services Research","Patient-Centered Follow-Up","Organizational Intervention","Pulmonary Function Tests","Quality of Life","Patient Experience","Carbon Footprint","Multidisciplinary Care","2026-04-06",{"date":145,"type":36},"2026-04-09",{"date":147,"type":36},"2026-03-09",{"date":149,"type":20},"2028-03-01",{"name":151,"class":152},"Hospital de Granollers","OTHER",1,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":30,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":21,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":166,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":4},"100631661","phase-3-evaluating-the-efficacy-and-safety-of-of-hsk44459-in-people-with-progressive-pulmonary-fibrosis-100631661","NCT07503587","Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis","A Randomised, Double-blind, Placebo-controlled Parallel Group Phase III Clinical Study Evaluating the Efficacy and Safety of HSK44459 Tablets in Subjects With Progressive Pulmonary Fibrosis","Inclusion Criteria:\n\n1. Adults aged ≥18 year.\n2. Diagnosis of PPF other than IPF prior to screening or during the screening period.\n3. Patients must meet either of the following conditions:\n\n1\\. not on therapy with nintedanib or pirfenidone for at least 8 weeks prior to screening and during the screening period, and not planning to start or restart antiibrotic therapy.\n\n2.on stable therapy with nintedanib or pirfenidone for at least 12 weeks prior to screening and during the screening period.\n\n4.Percentage Predicted Forced Vital Capacity (ppFVC) ≥45% at screening period. 5.Diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for haemoglobin \\[Hb\\]) ≥ 25% and \\\u003C90% of predicted normal at screening period .\n\nExclusion Criteria:\n\n1. Clinically significant airways obstruction (Forced Expiratory Volume in One Second (FEV1)\u002FForced Vital Capacity (FVC) \\\u003C 0.7) at screening.\n2. In the opinion of the Investigator, other clinically significant pulmonary abnormalities.\n3. Acute ILD exacerbation within 3 months prior to screening and\u002For during the screening period.\n4. History of malignancy within 5 years prior to screening.\n5. History of vasculitis.",{"count":162,"type":20},378,[23],"This study is open to adults with PPF . The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.",[26],"NOT_YET_RECRUITING","2026-03-25",{"date":169,"type":36},"2026-03-31",{"date":171,"type":20},"2026-04-05",{"date":173,"type":20},"2029-03-01",{"name":175,"class":43},"Haisco Pharmaceutical Group Co., Ltd.",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":153},"100628805","study-on-the-efficacy-of-quercetin-intake-in-patients-with-fibrotic-interstitial-lung-diseases-100628805","NCT07466420","Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.","Study on the Efficacy of Quercetin Intake in Patients With Idiopathic Pulmonary Fibrosis and Non-Idiopathic Pulmonary Fibrosis. A Two-arm, Prospective Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n* Patients with an established diagnosis of IPF and Fibrotic ILD and will be eligible to participate in the study.\n* The use of the approved standard of care antifibrotic therapy, either nintedanib or pirfenidone, and immunosuppressive therapy will be allowed as standard of care.\n\nExclusion Criteria:\n\n* Subjects with a result of FeNO\\>25 ppb will be excluded from the study to ensure that no other pulmonary diseases, such as asthma, are present.\n* Patients who do not initiate quercetin within the first week after their baseline visit.",{"count":184,"type":20},100,[118],"Fibrotic interstitial lung diseases (F-ILDs), including both idiopathic pulmonary fibrosis (IPF) and non-IPF, are chronic and progressive lung diseases characterized by excessive scarring of lung tissue, leading to declining lung function, respiratory failure, and high mortality, despite the currently approved antifibrotic treatment. While its exact cause remains unknown, pulmonary fibrosis is strongly linked to aging, genetic predisposition, environmental factors, and cellular senescence. Ongoing research aims to identify reliable biomarkers and develop targeted treatments to enhance patient outcomes.\n\nThis randomized controlled trial will examine the effects of quercetin supplementation (500 mg\u002Fday for two 12-week cycles, with one 8-week washout periods) on telomere length, senescence-associated secretory phenotype (SASP) factors, and lung function in patients with IPF and F-ILDs. A total of 100 patients will be recruited, with half receiving quercetin (despite their standard of care therapy) and the other half receiving standard care (SOC). Primary outcomes will include changes in telomere length, SASP protein levels (IL-6, MMPs), fractional exhaled nitric oxide (FeNO), spirometry (FVC decline), and oscillometry measurements. Additionally, quality of life will be assessed using the L-IPF Questionnaire.\n\nThis study aims to explore quercetin's potential to reduce fibrosis, decrease inflammation, and improve lung function in F-ILDs, offering new insights into potential novel strategies for F-ILD management.",[188,59,26],"Fibrotic Interstitial Lungs Diseases",{"date":190,"type":36},"2026-03-12",{"date":192,"type":36},"2026-01-26",{"date":194,"type":20},"2029-01-31",{"name":196,"class":152},"Katerina M. Antoniou",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":21,"phases":206,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":153},"100613643","support-t-in-patients-with-progressive-pulmonary-fibrosis-and-their-caregivers-100613643","NCT07269262","SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers","Feasibility and Acceptability of a Mobile Application \"SUPPORT-T\" to Increase Equitable Access to Palliative Care in Patients With Progressive Pulmonary Fibrosis (PPF) and Their Caregivers","Inclusion Criteria:\n\n* Adults ≥18 years\n* Confirmed diagnosis of PPF\n* English or Spanish speaking\n\nCaregiver Inclusion Criteria:\n\n* adult, ≥ 18 years old\n* Designated and identified by patient as providing most of the emotional, financial, and\u002For physical support (i.e., the individual most involved in care, does not have to live with patient)\n* Able to speak and understand English.\n\nExclusion Criteria:\n\n\\-",{"count":205,"type":20},170,[118],"This pilot randomized controlled trial evaluates the feasibility, acceptability, and accessibility of SUPPORT-T, a digitally delivered palliative care intervention for patients with Progressive Pulmonary Fibrosis (PPF) and their caregivers. The intervention includes a 9-week digital application guided by a nurse interventionist and quarterly virtual support groups over one year. Participants will be recruited from rural South Carolina and urban New York City. The study compares SUPPORT-T to Enhanced Usual Care and aims to inform a future multi-site trial.",[26,27],[210,121],"Education","2026-01-29",{"date":213,"type":36},"2026-02-02",{"date":215,"type":36},"2026-01-13",{"date":217,"type":20},"2027-10-01",{"name":219,"class":152},"Medical University of South Carolina",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":153},"100618476","a-pilot-study-to-assess-body-mass-composition-measurement-using-bia-and-muscle-ultrasound-in-ipf-and-ppf-patients-on-anti-fibrotic-medications-100618476","NCT07332117","A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications","AF-BMC","Inclusion Criteria:\n\n* A diagnosis of Idiopathic pulmonary fibrosis or progressive pulmonary fibrosis\n* Newly commencing anti-fibrotic medication (either nintedanib or pirfenidone)\n* Subject aged \\> 18 years\n* Able to willingly give consent\n\nExclusion Criteria:\n\n* Co-morbidities currently requiring enteral feeding\n* Weight loss \\> 10% in preceding 3-6 months\n* Significant musculoskeletal issues that may impact muscle mass\n* End of life care (expected \\\u003C 6 weeks left to live)\n* Previous anti-fibrotic use\n* Currently on \\> Prednisolone 10mg daily\n* Presence of implantable cardioverter defibrillator (ICD) or permanent pacemaker (PPM)\n* Heart failure\n* Pregnancy",{"count":228,"type":20},30,"OBSERVATIONAL","To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound",[59,26],[233,234,235],"bioimpedance analysis","muscle ultrasound","body composition","2025-12-31",{"date":238,"type":36},"2026-01-12",{"date":240,"type":36},"2025-09-09",{"date":242,"type":20},"2026-04",{"name":244,"class":152},"Royal Brompton & Harefield NHS Foundation Trust",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":256,"conditions":257,"keywords":258,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":271},"100581824","prospective-phenotyping-and-multi-omic-endotyping-of-progressive-pulmonary-fibrosis-100581824","NCT06855329","PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis","PRIME-PPF: PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis","PRIME-PPF","Inclusion Criteria:\n\n* Age 18-80 years with a diagnosis of non-IPF fibrosing ILD due to CTD-ILD, fHP, or non-IPF IIP based on central review\n* Diagnosis of Fibrotic ILD as determined by site investigator.\n* Willingness to comply with study procedures and follow-up.\n* Provide written informed consent.\n\nExclusion Criteria:\n\n* Site diagnosis of fibrosing ILD \\>5 years prior to Visit 1 (Screening and Baseline Visit).\n* Minimal ILD, defined as reticular opacities and\u002For ground-glass opacities without architectural distortion (traction bronchiolectasis\u002Fbronchiectasis or honeycombing) affecting \\\u003C 5% of the lung on centralized evaluation of HRCT at Visit 1 (Screening and Baseline Visit). High quality historical chest HRCT may be used if performed within 90 days prior to Visit 1.\n* Extent of emphysema \\>15% of total lung volume or greater than extent of fibrosis based on central, qualitative assessment of HRCT at Visit 1. High quality historical chest HRCT may be used if performed within 90 days prior to Visit 1.\n* Active malignancy within one year prior to Visit 1 (except for non-melanoma skin cancer requiring local treatment).\n* Inability to complete full PFT (spirometry and DLCO) at Visit 1. Historical PFT may be used if performed within 90 days prior to Visit 1.\n* Taking nintedanib or nerandomilast at Visit 1.\n* Pregnancy at screening or plans to become pregnant during follow-up.\n* Participation in an interventional clinical trial for fibrotic ILD at the time of Visit 1, or receipt of an investigational drug within the previous 4 weeks of the enrollment visit (Visit 1) or 5 times the half-life, if longer.","80 Years",{"count":255,"type":20},500,"This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over time, and 2) Determine whether multi-dimensional PPF prediction outperforms component approaches.",[26,27],[259,260,261,251,30],"Progressive pulmonary fibrosis","Interstitial lung disease","PRIME","2025-09-16",{"date":264,"type":36},"2025-09-22",{"date":266,"type":36},"2025-05-01",{"date":268,"type":20},"2029-12",{"name":270,"class":152},"University of Massachusetts, Worcester",13]